SWOG S1400: A Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
This study is for patients with advanced squamous cell lung cancer that have completed no more than one type of chemotherapy.
This study looks at DNA from each patient’s tumor to learn what genetic changes may be driving the growth of cancer.
The purpose of this study is to compare the effects of investigational drugs targeted at the specific genetic changes found in a patient’s lung cancer tumor to the usual approach for treating this type of lung cancer.
Patients will be followed for 3 years after registration into the study.